Valeant Pharmaceuticals Intern… (NYSE:VRX)

Rite Aid, Valeant Drop into Tuesday’s 52-Week Low Club

March 21, 2017: Here are four stocks trading with relatively heavy volume among 113 equities making new 52-week lows in Tuesday's session. On the NYSE, decliners led advancers by nearly ...
Read Full Story »

Is Valeant Finished Now That Ackman Is Out of the Picture?

Valeant Pharmaceuticals International Inc. (NYSE: VRX) saw its shares hit a multiyear low on Tuesday after it was announced that Bill Ackman would be selling off his stake in the ...
Read Full Story »

Stifel Out With 4 Contrarian Stocks to Buy With Big Upside Potential

The market feels very heavy, and with big announcements coming this week, things may be poised to get a little volatile. The Federal Reserve meeting, along with numerous other central ...
Read Full Story »

Valeant, JC Penney Plunge Into Tuesday’s 52-Week Low Club

March 13, 2017: Here are four stocks trading with relatively heavy volume among 116 equities making new 52-week lows in Tuesday's session. On the NYSE, decliners led advancers by about ...
Read Full Story »

Valeant, DryShips Plunge into Tuesday’s 52-Week Low Club

March 7, 2017: Here are four stocks trading with heavy volume among 121 equities making new 52-week lows in Tuesday's session. On the NYSE, decliners led advancers by about 7 ...
Read Full Story »

Rite Aid, Frontier Communications Tumble into Monday’s 52-Week Low Club

March 6, 2017: Here are four stocks trading with heavy volume among 111 equities making new 52-week lows in Monday's session. On the NYSE, advancers led decliners by about 8 ...
Read Full Story »

Why One Key Analyst Believes That Valeant Is Kicking the Can in Its Restructuring Deal

Valeant Pharmaceuticals International Inc. (NYSE: VRX) has been in the spotlight for a couple years and is now fighting to stay alive. The company initially brought in new executives and ...
Read Full Story »
Depressed Senior Adult Man With Stacks of Papers and Envelopes

Why Analysts Are Looking at Valeant Pharma Differently After Earnings

Valeant Pharmaceuticals International Inc. (NYSE: VRX) saw its shares hit a multiyear low this past week. There was hope for a turnaround when Joe Papa took over as chief executive officer, but ...
Read Full Story »
Stock Price

Target, Valeant Slide into Friday’s 52-Week Low Club

March 3, 2017: Here are four stocks trading with heavy volume among 71 equities making new 52-week lows in Friday's session. On the NYSE, advancers led decliners by about 8 ...
Read Full Story »
ashamed businessman

Why Valeant Missed the Mark Despite an Earnings Beat

When Valeant Pharmaceuticals International Inc. (NYSE: VRX) reported its fourth-quarter financial results before the markets opened on Tuesday, the company said that it had $1.26 in EPS and $2.4 billion ...
Read Full Story »
ThinkstockPhotos-475180302

6 Key Earnings to Look For This Week

The broad markets hit new highs last week, even though the fourth-quarter earnings reporting season is all but over. A few stragglers are still lining up to report this week. ...
Read Full Story »
automatic inspection machine

Top Biopharma Movers of the Past Week

A few biopharma companies made massive runs this past week. The health care sector was in trouble over the past year, under fire from congressional hearings and politicians on the ...
Read Full Story »
research

Tuesday’s Top Biopharma Movers

A few biopharma companies made massive runs on Tuesday morning. The health care sector was in trouble over the past year, under fire from congressional hearings and politicians on the ...
Read Full Story »
Medical vaccine in shoulder, vaccination

Why This FDA Approval for Valeant Is Not as Good as First Thought

Valeant Pharmaceuticals International Inc. (NYSE: VRX) received a key U.S. Food and Drug Administration (FDA) approval early on Thursday, but it seems to be a mixed blessing. Initially shares were higher ...
Read Full Story »
100 dollar bills

Wednesday’s Top Biopharma Movers

Biotech and pharma companies were on the move Wednesday. A few of the smaller caps made tremendous gains on the day, while a couple of the major firms saw massive ...
Read Full Story »